{
    "nctId": "NCT04913532",
    "briefTitle": "Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer",
    "officialTitle": "A Phase II Trial of Evaluation of Acute Toxicity in Hypofractionation With Simultaneous Integrated Boost for Early Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, Surgery, Adjuvant Radiotherapy",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 40,
    "primaryOutcomeMeasure": "Acute Toxicity",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histopathologically confirmed breast cancer operated by breast conserving surgery with clear margins\n* Indication to adjuvant radiotherapy including boost radiotherapy\n* Clearly identified primary tumor region preferably by radiopaque clips\n* Primary wound healing after breast conserving therapy without signs of infection\n* Pre- and/or postoperative chemotherapy and endocrine therapy were permitted when indicated\n* Written informed consent\n\nExclusion Criteria:\n\n* Patients operated by mastectomy\n* No indication for boost radiation\n* Resection margins positive for disease or insufficient identification of the boost volume\n* Indication for radiotherapy of the regional lymph nodes\n* History of prior breast or thoracic radiotherapy\n* Extended postoperative seroma at the beginning of radiotherapy\n* Psychiatric disorders or psychological disabilities thought to adversely affect treatment compliance\n* Pregnant or lactating patients and woman of child bearing potential, who lacked effective contraception",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}